Pain Therapeutics reports the FDA Advisory Committee voted 14 to 3 against the approval of REMOXY ER (oxycodone extended-release capsules) for the management of pain
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 7, 2018 for completion of its review of the New Drug Application for REMOXY ER. (DRRX)
** the day before **
No comments:
Post a Comment